Roche's Avastin wins EU ovarian cancer nod; Mylan cuts 2014 forecast after Q2 profit drop;

@FiercePharma: ICYMI: This week's issue of FiercePharmaMarketing. Subscribe here, if you please | Follow @FiercePharma

@TracyStaton: Tops @FiercePharma over the weekend: Top Sanofi exec departs amid struggles in franchise. More | Follow @TracyStaton

@EricPFierce: Instead of buying counterfeit Viagra from China, this guy bought APIs and whipped up an ED drug in his home lab. More | Follow @EricPFierce

@CarlyHFierce: EMA accepts Pfizer app to expand Prevenar in adults. FierceVaccines story | Follow @CarlyHFierce

> The EU has approved Roche's ($RHHBY) Avastin for the hardest-to-treat form ovarian cancer. More

> Amid a 30% second-quarter profit dive, Mylan ($MYL) trimmed its full-year forecast and revenue outlook. Report (sub. req.)

> Walgreen ($WAG) agreed to acquire the remainder of Alliance Boots for about $5.27 billion and will not move its tax base to the U.K. More

> Astellas Pharma's European division has appointed Simon Dew as chief strategy officer and Jun Kono as VP of corporate strategy and communications. More

> Mallinckrodt ($MNK) raised its full-year guidance on narrower losses in Q3. Report

> Daiichi Sankyo and Charleston Laboratories have announced a collaboration to commercialize the latter's hydrocodone products in the U.S. Report

> The FDA has green-lighted Zydus Cadila's Potassium Citrate ER tablets for use in prevention of kidney stones. Report

> The FDA has approved The Medicines Co.'s ($MDCO) acute skin infection drug. Report

Medical Device News

@FierceMedDev: Carnegie Mellon team creates self-assembling nanofibers for shaped delivery vehicles. FierceDrugDelivery story | Follow @FierceMedDev

@StacyALawrence: Ten big med tech companies add 25,000 jobs in 2013. Article | Follow @StacyALawrence

@VarunSaxena2: Stentys ditches bare metal stents as customers move to drug-eluting versions. ICYMI from FierceDrugDelivery | Follow @VarunSaxena2

@MichaelGFierce: Thin and strong, graphene sheets form spheres spontaneously for drug release. More from FierceDrugDelivery | Follow @MichaelGFierce

@EmilyWFierce: Saving Lives at Birth initiative developing innovative devices to improve infant health in underserved communities. More from National Geographic | Follow @EmilyWFierce

> St. Jude Medical seals the deal on NeuroTherm to gain ground in neuromodulation. News

> NeuroPace RNS Stimulator secures add-on payments from CMS. Story

> Alere to complete strategic review by year-end. Article

Biotech News

@FierceBiotech: Daiichi Sankyo bets up to $650M on Charleston's pain potential. Article | Follow @FierceBiotech

@JohnCFierce: ICYMI yesterday: Interesting fact, when DoD stopped $SRPT's work on Ebola, they left in a provision to reactivate the $291M contract. Article | Follow @JohnCFierce

@DamianFierce: RT @FierceBiotech: New special report: The top 15 late-stage blockbusters in the pipeline. Feature | Follow @DamianFierce

> Novo picks up the pace with its next-gen insulin, eyeing a 2016 U.S. debut. More

> Hype and hope compete as overnight stardom engulfs untried Ebola drugs. Report

> After a 6-year delay, Medicines Co. bags FDA approval for once-troubled antibiotic. News

Vaccines News

> Bavarian Nordic the only bidder for Canada's smallpox vax supply. Item

> NIH: Ebola vaccine trial could begin as early as September. Report

> Affiris clears Phase I with Parkinson's vaccine candidate. Story

> U.K. and Novartis begin price negotiations on Bexsero. More

> Sanofi dengue vaccine filings could come as soon as next year's Q1, CEO says. Article

Pharma Manufacturing News

> Alvogen adds Asian manufacturing capacity in $187M Dream Pharma buyout. News

> Impax looking to use $400M cash stash for M&A. Report

> Fresenius awaiting FDA reinspection at plants in NY, India. Story

> Ebola outbreak puts spotlight on tobacco-based drug production. More

> Cubist issues third recall in 12 months after another CMO quality failing. Article

And Finally... Biogenesis founder Anthony Bosch, the man at the center of Major League Baseball's recent performance-enhancing drug scandal, has surrendered to the Drug Enforcement Agency (DEA). Article (sub. req.)